Credit Suisse’s Aldeyra Therapeutics ALDX Stock Holding History

Credit Suisse’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-54,203	Closed	-$362K	–	3053
2023 Q3	$362K	Sell	54,203 -10,073	-16%	-$74.7K	﹤0.01%	2855
2023 Q2	$539K	Buy	+64,276	New	+$633K	﹤0.01%	2737
2022 Q3	–	Sell	-26	Closed	–	–	4020
2022 Q2	$0	Buy	+26	New	+$89	﹤0.01%	3893
2021 Q2	–	Sell	-13,040	Closed	-$155K	–	4438
2021 Q1	$155K	Buy	+13,040	New	+$150K	﹤0.01%	4160

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's ALDX Position: Q4 2023 in Review

Credit Suisse sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 54,203 shares — an estimated $362K sold.

Credit Suisse first reported a position in ALDX in Q1 2021 and held it in 4 quarters. The position peaked at $539K in Q2 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

Credit Suisse reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
Credit Suisse sold 54,203 Aldeyra Therapeutics shares in Q4 2023, an estimated $362K.
Credit Suisse first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 4 quarters.
Credit Suisse's Aldeyra Therapeutics position peaked at $539K in Q2 2023.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.